Stifel Financial
PVCT

Stifel Financial’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Stifel Financial’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-35,000
Closed -$14K – 2585
2016
Q2 		$14K Buy
+35,000
New +$13.3K ﹤0.01% 2492

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Stifel Financial's PVCT Position: Q3 2016 in Review

Stifel Financial sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2016, closing a stake of 35,000 shares — an estimated $14K sold.

Stifel Financial first reported a position in PVCT in Q2 2016 and held it in 1 quarter. The position peaked at $14K in Q2 2016. 41 funds tracked by Wall St. Rank hold PVCT as of Q3 2016.

  • Stifel Financial reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2016 after selling out during the quarter.
  • Stifel Financial sold 35,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2016, an estimated $14K.
  • Stifel Financial first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2016 and held it in 1 quarter.
  • Stifel Financial's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $14K in Q2 2016.
  • 41 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2016.

Based on Stifel Financial's 13F filing for Q3 2016, filed 15 Nov 2016.